Ibogaine and the Bicameral Mind: The Definitive Clinical and Cultural Guide to Ibogaine Publishes Today

• Ambio Life Sciences CEO Jonathan Dickinson draws on 17 years of clinical practice and Bwiti initiation to bridge tradition and modern neuroscience
• Foreword by former Texas Governor Rick Perry; praise from Rick Doblin (MAPS), ethnopharmacologist Dennis McKenna, and NYT bestseller Norman Ohler
• Released as White House Executive Order Names Ibogaine a Federal Research Priority

Vancouver, BRITISH COLUMBIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ambio Life Sciences, the global leader in integrative ibogaine treatment, today announced the release of Ibogaine and the Bicameral Mind. Written by Ambio CEO and Co-Founder, Jonathan Dickinson, it is the most comprehensive book on ibogaine pharmacology, history, and clinical application ever published.  

Ibogaine and the Bicameral Mind is the most comprehensive book on ibogaine. Called “a compelling call for further research” by Kirkus Reviews, it arrives as U.S. policy and public interest increasingly turn toward psychedelic medicine.

Released today by Inner Traditions/Park Street Press, the book arrives as demand for ibogaine treatment surges and U.S. federal policy accelerates toward broader research and patient access. 

“Most people are hearing about ibogaine for the first time now, as its value becomes increasingly clear, but this field has a long history. Quite a lot of work has been done to develop the ibogaine treatment model emerging today,” Dickinson said. 

Dickinson is one of the world’s leading experts on ibogaine. Twice initiated into the Bwiti tradition of Gabon – Dissoumba/Fang lineage in 2014 and Missoko lineage in 2022 – he secured the first license to export iboga from Gabon under the Nagoya Protocol, establishing a framework for ethical, benefit-sharing sourcing. 

Introducing Ibogaine’s “Bicameral” State 

The book's central thesis is that ibogaine induces a "bicameral state" – a liminal mode of being in which ancient voices, archetypes, and internal guidance systems emerge, often catalyzing profound reorganization of memory, identity, and behavior.  

The term draws on psychologist Julian Jaynes' 1976 work The Origin of Consciousness in the Breakdown of the Bicameral Mind, which theorized that human consciousness once operated through a divided mental structure. Dickinson extends this framework into a new lens for understanding altered states of consciousness and their therapeutic potential. 

A Challenge to Modern Psychiatry 

Beyond the bicameral framework, the book argues that modern psychiatry has misdiagnosed a generation of veterans. Dickinson points to mild traumatic brain injury (mTBI), the ‘signature wound’ of blast exposure in modern warfare, which is frequently mistreated as PTSD despite the DSM-5's own guidance against psychiatric diagnosis when symptoms stem from a medical condition. He argues this leads to a reliance on SSRIs to manage symptoms of what may be an underlying physical injury requiring regeneration, not suppression.  

Drawing on case studies and emerging research – including a landmark Stanford study conducted at Ambio Life Sciences associating ibogaine treatment with structural brain changes and vastly improved quality of life in veterans – the book explores ibogaine's neuroregenerative potential for TBI, Parkinson's, and other neurodegenerative conditions. 

“As its applications become better understood, ibogaine is emerging as a potentially revolutionary treatment for a broad spectrum of mental health and neurological conditions. Jonathan Dickinson has dedicated his life to bringing ibogaine to the world in a way that is both ethical and responsible, yet true to the spirit of the traditions that have chosen to share this gift with the world,” said globally renowned ethnopharmacologist, Dennis McKenna Ph.D.  

“Ibogaine and the Bicameral Mind tells the story of his decades-long devotion to this work, while also being the currently most comprehensive and definitive source of information on ibogaine in all of its complexity.” 

Published as U.S. Policy and Public Demand Turns Toward Psychedelic Medicine 

The book arrives just months after President Trump signed Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," in April. The order directs the FDA and DEA to establish Right to Try access pathways for ibogaine and other psychedelic compounds, allocates federal funding to support state-level research programs, and calls for expedited rescheduling review for substances that complete Phase 3 clinical trials. Ibogaine and the Bicameral Mind offers the clinical and cultural grounding for a medicine now moving toward the mainstream of American healthcare policy. 

The release comes amid an unprecedented rise in interest in ibogaine treatment. Ambio Life Sciences has grown alongside that demand, now operating seven clinics in Mexico and one in Malta – including dedicated facilities for medically supervised detoxification and for patients with neurodegenerative conditions. As the world's only transcontinental, integrative ibogaine provider, Ambio has treated thousands of patients seeking relief from addiction, traumatic brain injury, mental health conditions, and neurodegenerative disease. 

Ibogaine and the Bicameral Mind is available now at jonathandickinson.ca, Inner Traditions, Barnes and Noble, Amazon, Hudson Bookseller, Target, and Walmart.  

About Ambio Life Sciences 

Ambio Life Sciences is the global leader in integrative ibogaine treatment, setting a new benchmark for clinical quality, patient safety, and therapeutic innovation. With over 50 years of combined experience, Ambio’s founding team brings together unmatched expertise in medical protocols, research leadership, and ethical ibogaine care. 

Operating world-class clinics in Mexico and Malta, Ambio delivers medically supervised programs for people with addiction, traumatic brain injury, psychological trauma, chronic pain, and neurodegenerative conditions. The company also works with high-performance individuals – including special operations veterans, elite athletes, and creative professionals – seeking sustainable personal optimization and recovery from medically complex conditions. 

As the world’s only transcontinental and integrative ibogaine provider, Ambio helps individuals create lasting, adaptive change in their lives. Driven by science and grounded in deep clinical experience, Ambio is advancing a new paradigm in mental health and recovery, one that empowers individuals to reclaim agency and lead more adaptive, meaningful lives. 

 

 

 

 

 

Jonathan Dickinson is CEO and Co-Founder of Ambio Life Sciences and a leading ibogaine expert. A Mexico-licensed psychologist, he developed foundational safety guidelines and has published widely on ibogaine, including Ibogaine and the Bicameral Mind.

Press Inquiries

Media Inquiries Contact: 

Victoria Dekker 
Chief Communications Officer, Ambio Life Sciences 
Email: victoria.dekker@ambio.life 
Website: https://ambio.life/ 

Publisher Inquiries Contact:

Ashley Kolesnik 
Publicity Manager, Inner Traditions/Park Street Press 
Email: ashleyk@innertraditions.com